Invivyd
Waltham
MA
United States
41 articles with Invivyd
-
Invivyd Reports Full Year 2022 Financial Results and Business Highlights
3/23/2023
Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced financial results for the year ended December 31, 2022, and recent business highlights.
-
Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19
3/22/2023
Invivyd, Inc. (Nasdaq: IVVD) today announced the publication of research in the peer-reviewed journal Science Translational Medicine describing a model for evaluating biomarker correlates of protection for monoclonal antibodies (mAb) against symptomatic COVID-19.
-
Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights
3/16/2023
Invivyd, Inc. today announced that it will host a conference call on Thursday, March 23, 2023, at 4:30 p.m. ET to discuss its financial results for the full year ended December 31, 2022, and recent business highlights.
-
Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies
3/6/2023
Invivyd, Inc., a clinical stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, announces the election of VYD222 to advance into the clinic as a novel monoclonal antibody therapeutic option for COVID-19.
-
Invivyd Announces Changes to Executive Team
2/3/2023
Invivyd, Inc. today announced that Laura Walker, Ph.D., the company’s chief scientific officer and co-founder, decided to leave the company to pursue other opportunities.
-
Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop
12/19/2022
Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, was invited to participate in an FDA-EMA workshop on SARS-CoV-2 monoclonal antibodies held on December 15, 2022.
-
Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer
12/6/2022
Invivyd, Inc. announced the appointment of Jeremy Gowler as chief operating and commercial officer, effective December 16, 2022, and the promotion of Pete Schmidt, M.D. to chief medical officer, effective immediately.
-
Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
11/17/2022
Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced a partnership with Population Health Partners, L.P. (PHP) a global life-science firm dedicated to solving the health and economic challenges presented by prevalent diseases.
-
Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
11/10/2022
Invivyd, Inc. announced financial results and business highlights for the third quarter ended September 30, 2022.
-
Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference
11/9/2022
Invivyd, Inc today announced David Hering, chief executive officer of Invivyd, is scheduled to participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 4:25 p.m. GMT.
-
Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Highlights
11/2/2022
Invivyd, Inc. announced that it will host a conference call on Thursday, November 10, 2022, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2022, and recent business highlights.
-
Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors
10/24/2022
Invivyd, Inc., a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, announced the appointment of Christine Lindenboom, senior vice president investor relations & corporate communications at Alnylam Pharmaceuticals, Inc., to its board of directors.
-
Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform
10/13/2022
Invivyd announced the appointment of Fred Driscoll as interim CFO as well as headcount changes to align resources to its key programs.
-
Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022
10/12/2022
Invivyd, (Nasdaq: IVVD), formerly Adagio Therapeutics (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases announced today that it will have four poster presentations at ID Week 2022.
-
Adagio, Aravive, PolyPid, Harpoon, Durect, Nitrase, Kallyope, TScan and many more made major leadership decisions this week.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Although it looks that we’re on the downside of the COVID-19 pandemic in the U.S., biopharma companies are still working on developing better treatments and preventions.
-
Adagio Therapeutics has appointed current COO David Hering as interim CEO, replacing Tillman Gerngross, Ph.D., who communicated his intention to resign in mid-February.
-
Weeks after announcing that its lead monoclonal antibody was demonstrating efficacy against the Omicron variant, Adagio Therapeutics CEO Tillman Gerngross steps down.
-
Amagma Therapeutics announced a licensing agreement with Innovent Biologics for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC Platform.